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For many years, one of the main aims of neoadjuvant 
therapy has been to identify short term endpoints that 
will predict for long-term outcome in adjuvant treatment. 
Th   e advantages are obvious: in contrast to adjuvant trials, 
neoadjuvant trials require hundreds rather than 
thousands of patients, are very much less expensive to 
run and produce outcome data many years earlier.
A key primary endpoint for neoadjuvant trials has been 
objective clinical response and this still remains the case 
[1]. Nevertheless, major studies have frequently shown 
that clinical response, including complete clinical remis-
sion, does not predict for long-term outcome. For 
example, in the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) B-18 trial no diﬀ  erence in out-
come was seen between patients who achieved clinical 
response versus those who did not [2]. Likewise, in the 
NSABP B-27 trial in which 2,411 patients were random-
ised to neoadjuvant adriamycin/cyclophospha  mide (AC) 
versus the same treatment followed by sequential 
docetaxel, the complete response rate was 64% for the 
sequential, docetaxel-containing arm compared with 40% 
for the AC arm alone (P < 0.001), but no signiﬁ  cant 
diﬀ  erence was seen in long-term survival [3,4]. Likewise, 
for neoadjuvant endocrine therapy, the IMPACT 
(Immediate Preopera  tive Anastrozole, Tamoxifen, or 
Combined With Tamoxifen) trial compared neo  adjuvant 
anastrazole versus tamoxifen versus the combination and 
was the neoadjuvant equivalent of the ATAC (Arimidex, 
Tamoxifen, Alone or in Combination) adjuvant trial. No 
signiﬁ  cant diﬀ  erence was seen in response rate between 
the three arms of IMPACT [5] and this failed, therefore, 
to correlate with the long-term disease-free survival 
advantage of anastrazole in ATAC. Likewise, in the 
IMPACT trial a large diﬀ  erence was seen in response 
rates for patients with human epidermal growth factor 
receptor 2 (HER2)-positive tumours in favour of 
anastrazole (7 of 12 responders; 58%) compared with 
tamoxifen (2 of 9 responders; 22%) and yet no selective 
disease-free survival advantage for anastrazole over 
tamoxifen in patients with HER2-positive tumours was 
subsequently seen in ATAC [6]. A possible explana  tion 
for this is that it is entirely possible that tumour growth 
rate may be slowed by neoadjuvant therapy (as measured, 
for example, by a reduction in proliferation factor Ki67) 
without a formal clinical response being achieved but 
with a consequent gain in relapse free survival. In the 
IMPACT trial, for example, only 37% of tumours 
achieved an objective clinical response rate to anastrazole 
whereas 75% had a signiﬁ  cant reduction in Ki67 [7].
In contrast to clinical complete remission, pathological 
complete remission (pCR) (involving complete patho-
logical disappearance of tumour from most breast and 
axillary nodes) following neoadjuvant chemotherapy has 
been shown to be of major prognostic signiﬁ  cance in 
many studies [2,8]. Diﬀ  erences in pCR have also some-
times been shown to reﬂ  ect  diﬀ   erences in long-term 
outcome in randomised trials. For example, in patients 
with HER2-positive tumours, two major trials have 
shown that the addition of trastuzumab to neoadjuvant 
chemotherapy achieves a major increase in pCR rates 
[9,10], results that accurately reﬂ  ect the very signiﬁ  cant 
disease-free survival and overall survival improvement 
achieved with the addition of trastuzumab to chemo-
therapy in adjuvant trials [11,12].
Th  ere are, however, problems with pCR. First, not all 
trials have shown a correlation between pCR and long-
term outcome. In particular, in the largest neoadjuvant 
chemotherapy trial, NSABP B-27, sequential treatment 
with docetaxel after AC achieved a 26% pCR rate 
compared with 13% for AC alone (P < 0.001) and yet no 
signiﬁ   cant survival diﬀ   erence subse  quently emerged 
between the two arms [3,4]. Second, pCR rates following 
neoadjuvant chemotherapy are relatively low, ranging 
from around 10 to 20%; this end point applies, therefore, 
to only a minority of patients and misses many others 
who also have a good prognosis. In particular, the pCR 
rate following chemotherapy is very low in patients with 
oestrogen receptor-positive tumours at around 8% [13] 
and yet many of these patients not achieving pCR 
nevertheless have an excellent prog  nosis. Th   e next issue is  © 2010 BioMed Central Ltd
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© 2010 BioMed Central Ltdthat pCR is very rarely seen following neoadjuvant 
endocrine therapy and is not, therefore, a useful endpoint 
in this major subgroup. Finally pCR as an endpoint is 
uninformative until treat  ment has been completed and 
surgical excision carried out; it does not, therefore, allow 
for early changes in treatment.
Biological parameters predicting for pCR after 
chemotherapy, or better still predicting for long-term 
outcome irrespective of pCR, would therefore be very 
valuable. One such widely studied parameter is Ki67 as a 
measure of proliferation. Ki67 has been shown to predict 
for pCR after chemotherapy as has oestrogen receptor 
status, HER2 status and grade [14]. However, in this 
study only HER2 was predictive in multivariant analysis. 
In a review, Ki67 was predictive for pCR in six out of 
eight studies by univariate analysis but only one out of 
ﬁ   ve studies in multivariate analysis [15]. Th  ere is, 
however, a paradox with Ki67 since high levels, although 
predictive for pCR, nevertheless are associated with 
signiﬁ  cant adverse prognosis [14]. Th   e likely explanation 
for this paradox is that high Ki67 predicts for a minority 
of patients who will achieve pCR and do well but also for 
a majority who will not and will do badly.
A further problem with classical neoadjuvant therapy 
trials is that they nearly always relate to large cancers, 
usually with diameters of 3 cm or more. Th  e question 
arises as to whether outcome parameters in these 
accurately predict for outcome in smaller cancers 
associated with standard adjuvant therapy.
A possible solution to many of these problems is the 
use of short-term preoperative therapy for around 2 weeks 
before surgery. In the IMPACT trial of neo  adjuvant 
endocrine therapy described above we were able to show 
in multivariate analysis that higher Ki67 expression after 
2 weeks of endocrine therapy was statistically signiﬁ  -
cantly associated with lower recurrence-free survival 
(P = 0.004) whereas higher Ki67 expression at baseline 
prior to treatment was not. Th  ese ﬁ  ndings suggest that 
measurements of Ki67 and other molecular markers after 
short-term preoperative treatment may be more useful in 
predicting long-term outcome than similar parameters 
measured at baseline. Furthermore, the approach can be 
applied to all patients requiring adjuvant therapy, in 
contrast to the minority with large cancers eligible for 
classical neoadjuvant treatment, and results can be 
obtained quickly with the opportunity of changing therapy 
if required.
In conclusion, in standard neoadjuvant therapy, clinical 
response is an unreliable endpoint for outcome. pCR is a 
better predictor but is useful only in a minority of 
patients, is of no use for endocrine therapy and is too late 
to inﬂ  uence treatment. Th  e entire classical neoadjuvant 
approach is based on the uncertain premise that large 
primaries (which are uncommon) reﬂ  ect the treatment 
sensitivity of small primaries (which are common). Short 
duration (2 to 3 weeks) preoperative therapy could 
provide molecular endpoints reﬂ   ecting both innate 
tumour biology and treatment eﬀ  ect. Th   ese could involve 
the majority of patients with early breast cancer and this 
approach overcomes many of the limitations of classical 
neoadjuvant studies.
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